News for Healthier Living

ASCO: Targeted Therapy Combo Nearly Doubles Time Without Disease Progression for Patients with Advanced Colorectal Cancer

Updated results from the Phase 3 BREAKWATER trial, led by researchers at The University of Texas MD Anderson Cancer Center, demonstrated a 56% reduction in the risk of disease progression or death for patients with BRAF V600E mutant metastatic colorectal cancer treated with a targeted therapy combination.

June 1, 2026


June 5 2026

June 4 2026

June 3 2026

June 2 2026

June 1 2026

May 31 2026

May 30 2026

May 29 2026

May 28 2026

May 27 2026

May 26 2026

May 25 2026